AMD

An understanding of GA growth kinetics is key to addressing the pathophysiology of age-related macular degeneration

AMD treatment may become unrecognisable as gene therapies evolve

New financing will support the company's lead retinitis pigmentosa programme, among other projects

According to the company, the EMA’s opinion was based on the “totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package”

Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.

Investigators obtained data from genome‐wide association studies to examine the effects of instant coffee consumption

Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS, presented two studies involving the EZ line at this year’s International SPECTRALIS Symposium

Brazilian ANVISA has granted marketing authorisation for FYB201 (Ranivisio), a biosimilar to Lucentis.

Long-term benefits and vision preservation using an extended macular vision IOL

Three dose level cohorts of the small interfering RNA therapeutic were evaluated in a double-blind study

Investigators sought to understand the diagnostic path, symptoms, quality of life impact and coping mechanisms of patients with GA in western Europe and the United States

The phase 3 LUCERNE and TENAYA trials suggested that faricimab may allow clinicians to extend the interval between injections to up to 16 weeks after an initial loading phase

In an established animal model of age-related macular degeneration, Eleva’s recombinant human CPV-104 improved two hallmarks of the disease

Bangalore-based Eyestem will share more research findings on Eyecyte-RPE at this year's Association for Research in Vision and Ophthalmology meeting

Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration

Researchers assessed the costs to patients and caregivers in Germany, Bulgaria and the US

The Combination OPT-302 with Aflibercept Study (COAST) evaluated sozinibercept 2 mg in combination with aflibercept 2 mg for wet age-related macular degeneration

The study demonstrated that the number of injections needed gradually decreased during the follow-up period

Inherited retinal diseases have disease processes distinct from age-related macular degeneration and geographic atrophy, but may present with "phenocopy" clinical signs

A clinician panel illuminates current treatment paradigms and best practices for reducing treatment burden

One in vitro study included in the manuscript was conducted in collaboration with researchers at the University of Southhampton in the United Kingdom

Professor Anat Loewenstein, MD, speaks about her presentation from the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting

The authors evaluated shallow irregular pigment epithelial detachment, subretinal hyperreflective material, subretinal fluid, intraretinal fluid and other baseline OCT biomarkers

Panelists discuss how loading doses remain crucial for treatment-naive patients to achieve rapid disease control, while patients switching therapies may require modified approaches based on their prior treatment response and disease activity.

Panelists discuss how real-world evidence provides crucial insights into treatment effectiveness across diverse patient populations and clinical settings while highlighting challenges in maintaining clinical trial protocols’ stringent adherence and monitoring in everyday practice.

Panelists discuss how both medications demonstrate favorable safety profiles in clinical trials, with aflibercept 8 mg benefiting from extensive 2-mg safety data, while acknowledging the need to monitor intraocular pressure due to increased injection volume, particularly in at-risk patients.

Panelists discuss how faricimab’s dual inhibition of Ang-2 provides additional benefits in vascular stability and inflammation reduction beyond VEGF-A suppression alone, potentially leading to improved durability and treatment outcomes in selected patients.

The implant was tested in eyes of patients with bilateral age-related macular degeneration who underwent cataract surgery

Pavblu and Skojoy, both from Amgen, are indicated for the treatment of neovascular age-related macular degeneration